SURVYR

BNTX

BioNTech SE
$87.99
+$0.93 (1.07%)Oct 28 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-25%-15%-4%+6%+17%Oct 2025Oct 2026Apr 202652w high $124.0052w low $79.52
BNTXSPY
Wall St. Highest PT $144.47 (+64.2%) Wall St. Avg PT $117.27 (+33.3%)
$84$106$128$150$172POC $90Hi $144Avg $117
Underwater Drawdown %Max DD -29.7%Current -26.3%
0.0%-29.7%
Relative Strength vs SPY-31.0% vs SPYUnderperforming
+36%0%-36%
1W
−$3.30 (3.61%)
1M
−$11.09 (11.19%)
3M
−$4.96 (5.34%)
6M
−$13.58 (13.37%)
YTD
−$7.21 (7.57%)
1Y
−$17.04 (16.22%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
20 analysts · mean score 1.71
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$87.99
Average target$117.27
+$29.28 (+33.3%) upsideaverage target vs current price
CurrentAverageMedian
Low$76.25
Median$117.27
High$144.47
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-10-14 · Canaccord Genuity reiterated Buy on BNTX
Reiterated
2026-10-07 · Morgan Stanley reiterated Overweight on BNTX
Downgrade
2026-09-08 · BMO Capital downgraded BNTX from Outperform to Market Perform
Reiterated
2026-08-31 · Canaccord Genuity reiterated Buy on BNTX
Reiterated
2026-08-05 · Citigroup reiterated Buy on BNTX
Reiterated
2026-08-05 · Evercore ISI Group reiterated Outperform on BNTX
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$22.9B
P/E (next 12 months, estimated)-16.9
52-week range$79.52 – $124.00
Revenue growth (latest quarter vs a year ago)-59.5%
Dividend yieldNo dividend
Analyst consensusBuy (20)
Average analyst price target$117.27 (+33%)

What they do

BioNTech SE engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for BNTX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

BNTX earningsNext report in 5 days
Next report · quarter Sep 2026
Tue Nov 3, 2026Before the open
EPS consensus$0.76 range $0.42–$1.35
Revenue consensus$1.1B 11 analysts
Last 4 quarters · EPS vs estimate
Aug 4, 2026-$2.22est -$2.08−6.8%Below estimates
May 5, 2026-$1.95est -$1.92−1.6%Below estimates
Mar 10, 2026-$0.33est -$0.25−30.4%Below estimates
Nov 3, 2025-$0.12est $0.10−220.3%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 18:14:28 ET
24-1125-0325-0525-0825-1126-0326-0526-08-2.351.08
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$105.6M-59.5%
2026-03-31$118.1M–
2025-12-31$907.4M–
2025-09-30$1.5B–
2025-06-30$260.8M–

Recent dividends

2022-06-02: $2.111

News & catalysts

More news
Moderna’s Cancer-Vaccine Leak Spurs Panic Selling. Wall Street Wanted a Cure.
Barrons.com · Oct 23
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
24/7 Wall St. · Oct 23
Rating changes
Reiterated
2026-10-14 · Canaccord Genuity reiterated Buy on BNTX
Reiterated
2026-10-07 · Morgan Stanley reiterated Overweight on BNTX
Downgrade
2026-09-08 · BMO Capital downgraded BNTX from Outperform to Market Perform
Reiterated
2026-08-31 · Canaccord Genuity reiterated Buy on BNTX
Reiterated
2026-08-05 · Citigroup reiterated Buy on BNTX
Reiterated
2026-08-05 · Evercore ISI Group reiterated Outperform on BNTX

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Sahin Ugur
Chief Executive Officer, 10% owner · 2026-10-09
Sell
$3.5M
Sahin Ugur
Chief Executive Officer, 10% owner · 2026-10-08
Sell
$2.5M
Sahin Ugur
Chief Executive Officer, 10% owner · 2026-10-07
Sell
$2.3M
Sahin Ugur
Chief Executive Officer, 10% owner · 2026-10-06
Sell
$2.0M
Sahin Ugur
Chief Executive Officer, 10% owner · 2026-10-05
Sell
$7.0M
Sahin Ugur
Chief Executive Officer, 10% owner · 2026-10-02
Sell
$1.6M
Sahin Ugur
Chief Executive Officer, 10% owner · 2026-10-01
Sell
$1.7M
Sahin Ugur
Chief Executive Officer, 10% owner · 2026-09-30
Sell
$3.1M
Sahin Ugur
Chief Executive Officer, 10% owner · 2026-09-29
Sell
$3.3M
Sahin Ugur
Chief Executive Officer, 10% owner · 2026-09-28
Sell
$3.3M
Sahin Ugur
Chief Executive Officer, 10% owner · 2026-09-25
Sell
$2.7M
Sahin Ugur
Chief Executive Officer, 10% owner · 2026-09-24
Sell
$3.9M

Stats refreshed 2026-10-21 18:14:28 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026